1/13
12:37 pm
dcth
Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade [Seeking Alpha]
Low
Report
Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade [Seeking Alpha]
1/9
12:46 pm
dcth
Delcath Systems (NASDAQ:DCTH) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Low
Report
Delcath Systems (NASDAQ:DCTH) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
1/9
08:05 am
dcth
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
Low
Report
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
1/4
04:31 pm
dcth
Should New HEPZATO Subgroup Data and Delcath's Targeted Strategy Require Action From DCTH Investors? [Yahoo! Finance]
Low
Report
Should New HEPZATO Subgroup Data and Delcath's Targeted Strategy Require Action From DCTH Investors? [Yahoo! Finance]
1/1
08:34 am
dcth
Delcath Systems publishes results from subgroup analyses of FOCUS study [Yahoo! Finance]
Low
Report
Delcath Systems publishes results from subgroup analyses of FOCUS study [Yahoo! Finance]
12/31
08:17 am
dcth
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma [Yahoo! Finance]
Low
Report
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma [Yahoo! Finance]
12/31
08:00 am
dcth
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma
Low
Report
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma
12/23
12:39 pm
dcth
Delcath Systems, Inc. (NASDAQ:DCTH) is a favorite amongst institutional investors who own 51% [Yahoo! Finance]
Low
Report
Delcath Systems, Inc. (NASDAQ:DCTH) is a favorite amongst institutional investors who own 51% [Yahoo! Finance]
12/16
10:55 am
dcth
Here's What Hit Delcath Systems (DCTH) in Q3 [Yahoo! Finance]
Low
Report
Here's What Hit Delcath Systems (DCTH) in Q3 [Yahoo! Finance]
12/3
07:02 pm
dcth
Investors in Delcath Systems (NASDAQ:DCTH) have seen splendid returns of 221% over the past three years [Yahoo! Finance]
Medium
Report
Investors in Delcath Systems (NASDAQ:DCTH) have seen splendid returns of 221% over the past three years [Yahoo! Finance]
12/3
04:01 pm
dcth
Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
Low
Report
Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
12/2
03:41 pm
dcth
Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
02:05 pm
dcth
Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
11/20
04:30 pm
dcth
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program [Yahoo! Finance]
Medium
Report
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program [Yahoo! Finance]
11/20
04:01 pm
dcth
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
Medium
Report
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
11/20
01:34 pm
dcth
Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
08:36 am
dcth
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma [Yahoo! Finance]
Low
Report
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma [Yahoo! Finance]
11/18
08:00 am
dcth
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma
Low
Report
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma
11/18
05:22 am
dcth
H.C. Wainwright Reiterates a Buy on Delcath Systems (DCTH), Lowers the PT [Yahoo! Finance]
Low
Report
H.C. Wainwright Reiterates a Buy on Delcath Systems (DCTH), Lowers the PT [Yahoo! Finance]
11/14
04:01 pm
dcth
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/13
08:41 am
dcth
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients [Yahoo! Finance]
Medium
Report
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients [Yahoo! Finance]
11/13
08:30 am
dcth
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients
Medium
Report
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients
11/9
01:11 am
dcth
Delcath Systems (NASDAQ:DCTH) was downgraded by analysts at
Weiss Ratings from a "hold (c-)" rating to a "sell (d+)" rating.
Low
Report
Delcath Systems (NASDAQ:DCTH) was downgraded by analysts at
Weiss Ratings from a "hold (c-)" rating to a "sell (d+)" rating.
11/6
04:28 pm
dcth
Delcath Systems to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Neutral
Report
Delcath Systems to Participate in Upcoming Investor Conferences [Yahoo! Finance]
11/6
04:01 pm
dcth
Delcath Systems to Participate in Upcoming Investor Conferences
Neutral
Report
Delcath Systems to Participate in Upcoming Investor Conferences